Literature DB >> 15208139

Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success.

Ronald J Zagoria1, Ashley D Hawkins, Peter E Clark, M Craig Hall, Brian R Matlaga, Raymond B Dyer, Michael Y Chen.   

Abstract

OBJECTIVE: The objective of our study was to evaluate the success rate for radiofrequency ablation of renal tumors and to determine the risk of serious complications.
CONCLUSION: No serious complications occurred after 27 CT-guided radiofrequency ablation sessions in 22 patients. In total, no residual tumor was detected on follow-up contrast-enhanced CT or MRI 1-35 months (mean, 7 months) after final tumor ablation in 20 (91%) of 22 patients. Two patients with residual viable tumor deferred further treatment. Complete tumor ablation was achieved after a single treatment session in 83% of patients, and in 8% of patients after subsequent ablation sessions. Size was the major determinant for achieving tumor eradication with a single session of ablation, with all 11 tumors 3 cm or smaller being completely ablated after one session. Tumor location, histology, and the presence of renal disease did not correlate with treatment success. Contrast-enhanced CT performed immediately after ablation is reliable to exclude residual viable tumor. CT-guided radiofrequency ablation of renal tumors is safe and has a high rate of success in the treatment of small renal tumors, with no evidence of recurrence at midterm follow-up of treated patients.

Entities:  

Mesh:

Year:  2004        PMID: 15208139     DOI: 10.2214/ajr.183.1.1830201

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  25 in total

Review 1.  Image-guided radiofrequency ablation of renal cell carcinoma.

Authors:  Andreas Boss; Stephan Clasen; Markus Kuczyk; Fritz Schick; Philippe L Pereira
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

2.  Real-time US/cone-beam CT fusion imaging for percutaneous ablation of small renal tumours: a technical note.

Authors:  Lorenzo Monfardini; Nicolò Gennaro; Franco Orsi; Paolo Della Vigna; Guido Bonomo; Gianluca Varano; Luigi Solbiati; Giovanni Mauri
Journal:  Eur Radiol       Date:  2021-04-19       Impact factor: 5.315

Review 3.  Percutaneous ablation in the kidney.

Authors:  Aradhana M Venkatesan; Bradford J Wood; Debra A Gervais
Journal:  Radiology       Date:  2011-11       Impact factor: 11.105

Review 4.  Radiofrequency thermal ablation of renal tumors.

Authors:  Massimo De Filippo; Francesca Bozzetti; Rosa Martora; Raffaella Zagaria; Stefania Ferretti; Luca Macarini; Luca Brunese; Antonio Rotondo; Cristina Rossi
Journal:  Radiol Med       Date:  2014-07-15       Impact factor: 3.469

5.  Thermoablation of Renal Masses: The Urologist's Perspective.

Authors:  Phillip H Abbosh; Sam B Bhayani
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

Review 6.  Percutaneous radiofrequency ablation of renal cell carcinoma.

Authors:  Debra A Gervais; Ronald S Arellano; Peter R Mueller
Journal:  Eur Radiol       Date:  2005-03-09       Impact factor: 5.315

7.  Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis.

Authors:  David A Kunkle; Robert G Uzzo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

8.  MR imaging-guided interventions in the genitourinary tract: an evolving concept.

Authors:  Fiona M Fennessy; Kemal Tuncali; Paul R Morrison; Clare M Tempany
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-02       Impact factor: 2.266

Review 9.  Computed tomography and magnetic resonance imaging appearance of renal neoplasms after radiofrequency ablation and cryoablation.

Authors:  Satomi Kawamoto; Stephen B Solomon; David A Bluemke; Elliot K Fishman
Journal:  Semin Ultrasound CT MR       Date:  2009-04       Impact factor: 1.875

Review 10.  [Energy ablative therapy of renal tumours].

Authors:  H C Klingler
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.